Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score

ClinicalTrials.gov ID: NCT03386539

Public ClinicalTrials.gov record NCT03386539. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 7, 2026, 7:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase III Multicenter Open-label Randomized Clinical Trial Comparing Everolimus and Low Dose Tacrolimus to Tacrolimus and Mycophenolate Mofetil at 6 mo Post-Transplant to Prevent Long-term Complications After Pediatric Heart Transplantation

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The TEAMMATE Trial will enroll 210 pediatric heart transplant patients from 25 centers at 6 months post-transplant and follow each patient for 2.5 years. Half of the participants will receive everolimus and low-dose tacrolimus and the other half will receive tacrolimus and mycophenolate mofetil. The trial will determine which treatment is better at reducing the cumulative risk of coronary artery vasculopathy, chronic kidney disease and biopsy proven-acute cellular rejection without an increase in graft loss due to all causes (e.g. infection, PTLD, antibody mediated rejection).

Study identification

NCT ID
NCT03386539
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Boston Children's Hospital
Other
Enrollment
211 participants

Conditions and interventions

Eligibility (public fields only)

Age range
Up to 21 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 28, 2018
Primary completion
Apr 16, 2023
Completion
May 16, 2023
Last update posted
Jul 30, 2026

2018 – 2023

United States locations

U.S. sites
25
U.S. states
18
U.S. cities
24
Facility City State ZIP Site status
Children's of Alabama Birmingham Alabama 35233
Phoenix Children's Hospital Phoenix Arizona 85016
Loma Linda University Loma Linda California 92354
Children's Hospital Los Angeles Los Angeles California 90027
UCLA Mattel Children's Hospital Los Angeles California 90095
Stanford University Palo Alto California 94304
Children's Hospital Colorado Aurora Colorado 80045
Children's National Medical Center Washington D.C. District of Columbia 20010
University of Florida Congenital Heart Center Gainesville Florida 32610-0297
Joe DiMaggio Children's Hospital Hollywood Florida 33021
Children's Healthcare of Atlanta Emory Atlanta Georgia 30322
Lurie Children's Hospital Chicago Illinois 60611
Boston Children's Hospital Boston Massachusetts 02115
University of Michigan Medical Center Ann Arbor Michigan 48109
Washington University in St. Louis School of Medicine St Louis Missouri 63110
Children's Hospital of New York New York New York 10032
Children's Hospital at Montefiore The Bronx New York 10803
Cincinnati Children's Hospital Medical Center Cincinnati Ohio 45229
The Children's Hospital of Philadelphia Philadelphia Pennsylvania 19104
Children's Hospital of Pittsburgh of University of Pittsburgh School of Medicine Pittsburgh Pennsylvania 15224
Children's Health Dallas University of Texas Southwestern Dallas Texas 75235
Texas Children's Hospital Houston Texas 77027
Primary Children's Hospital Salt Lake City Utah 84132
Seattle Children's Hospital Seattle Washington 98105
Children's Hospital of Wisconsin Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03386539, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 30, 2026 · Synced Sep 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03386539 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →